| age group |
cohort |
10 |
5 |
age (group), age groups, three age groups |
| Age group 18-29 years |
cohort |
3 |
1 |
18–29 y, youngest age group |
| Age group 60-64 |
cohort |
2 |
2 |
|
| ageing |
phenotype |
4 |
4 |
aging, anti-ageing, cellular ageing phenotypes, organismal ageing phenotypes, pro-ageing |
| age of menarche |
phenotype |
5 |
3 |
menarche, menarche age |
| age of onset |
phenotype |
16 |
8 |
AO, AOO, AOS, earlier age of onset |
| age-related diseases |
phenotype |
3 |
1 |
age-related diseases |
| age-related macular degeneration |
phenotype |
18 |
8 |
AMD |
| aggression |
phenotype |
56 |
46 |
AGG, AGG measures, Aggression, Indirect AGG, MPNI aggression, Physical aggression, aggression, aggression rating, aggression ratings, aggression scores, aggressiona, aggressive behavior, aggressive behavior phenotype, aggressive behaviors, child's aggressive behavior, indirect aggression subscale, indirect aggression subtype, mother-reported AGG, mother-reported AGG at age 7, peer-directed aggressive behavior, self-report measure of aggression |
| aggressiveness |
phenotype |
5 |
2 |
|
| Agilent 2100 Bioanalyzer |
drug |
27 |
11 |
Agilent BioAnalyzer, Agilent Bioanalyzer, Agilent Bioanalyzer (Agilent Technologies USA), Agilent Bioanalyzer 2100, BioAnalyzer 2100, Bioanalyzer |
| aging |
phenotype |
19 |
11 |
Normal aging, age, age-related changes, age-related degeneration, ageing, aging cells, aging process, aging processes, normal chronological aging |
| agonist |
drug |
2 |
1 |
|
| agoraphobia |
phenotype |
12 |
5 |
|
| AGRE |
cohort |
2 |
1 |
AGRE collection, Autism Genetic Resource Exchange |
| agreeableness |
phenotype |
7 |
6 |
agreeableness domain |
| AGT |
gene |
2 |
2 |
angiotensinogen |
| AIMs |
variant |
4 |
3 |
Ancestry Informative Markers, SNP AIMs, ancestrally informative markers, ancestry informative markers |
| airflow obstruction |
phenotype |
5 |
4 |
|
| air pollution |
drug |
3 |
2 |
|
